-

05:58:15 PM

RXRX Stock News

RXRX - Recursion Pharmaceuticals Inc

06/20/22 7:55 AM

Nasdaq : RXRX

clinical trial

Recursion Announces Initiation of Phase 2/3 Trial for the Treatment of NF2-Mutated Meningiomas at Children's Tumor Foundation NF Conference

If successful, REC-2282 could be the first approved treatment for NF2 -mutated meningiomas, which are debilitating lesions that occur in approximately 33,000 patients per year REC-2282 has been granted Fast Track and Orphan Drug designations for NF2 meningiomas by the U.S. Food and Drug

RHEA-AI

very positive

06/02/22 7:55 AM

Nasdaq : RXRX

conferences

Recursion to Participate in Upcoming Investor Conferences

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:Jefferies Healthcare Conference — June 8 through

RHEA-AI

neutral

05/10/22 4:29 PM

Nasdaq : RXRX

earnings

Recursion Provides Business Updates and Reports First Quarter 2022 Financial Results

Enrolled the first participant in our Phase 2 clinical trial for CCM and dosed multiple participants Expecting to enroll the first participant in our Phase 2/3 clinical trial for progressive NF2 -mutated meningiomas in the second quarter 2022 Received Fast Track Designation for REC-4881, a

RHEA-AI

very positive

05/02/22 7:55 AM

Nasdaq : RXRX

conferences

Recursion to Participate in Upcoming Investor Conference

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conference:Bank of America 2022 Healthcare Conference — May 10

RHEA-AI

neutral

04/11/22 7:55 AM

Nasdaq : RXRX

Recursion is Granted Fast Track Designation for REC-4881 for the Potential Treatment of Familial Adenomatous Polyposis

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced that the U.S. Food and Drug Administration (FDA) has granted the company Fast Track designation for REC-4881 for the

RHEA-AI

very positive

03/31/22 7:55 AM

Nasdaq : RXRX

conferences

Recursion to Participate in Upcoming Investor Conferences

Recursion (NASDAQ: RXRX), the clinical-stage biotechnology company industrializing drug discovery by decoding biology, today announced its participation in the following upcoming investor conferences:Piper Sandler AI/Machine Learning Conference —

RHEA-AI

neutral

03/30/22 7:55 AM

Nasdaq : RXRX

Altitude Lab Announces First Cohort of Startups Close Over $50M in Seed Capital

Altitude Lab today announced its first cohort of startups raised $54M in seed funding while incubating at Altitude Lab. Founded by Recursion ® and the

RHEA-AI

neutral

03/24/22 7:55 AM

Nasdaq : RXRX

Recursion Publishes First Environmental, Social and Governance (ESG) Report

Releases inaugural report less than one year after becoming a publicly-traded company, demonstrating its strong commitment to ESG stewardship Announces new long-term commitments focused on net-zero greenhouse gas emissions, workforce diversity and philanthropy SALT LAKE CITY , March 24, 2022

RHEA-AI

very positive

03/23/22 7:55 AM

Nasdaq : RXRX

earnings

Recursion Provides Business Updates and Reports Fourth Quarter and Fiscal Year 2021 Financial Results

Announced a transformational collaboration with Roche and Genentech to build and navigate maps of biology in neuroscience and an indication in gastrointestinal oncology and to advance up to 40 novel potential medicines Expanded our collaboration with Bayer to include the use of Recursion's OS to

RHEA-AI

positive

03/18/22 7:55 AM

Nasdaq : RXRX

clinical trial

Recursion Announces Enrollment of First Patient in Phase 2 Trial for the Treatment of Cerebral Cavernous Malformation

Recursion's small molecule is the first therapeutic candidate to be advanced to an industry-sponsored clinical trial for cerebral cavernous malformation (CCM) CCM is a devastating neurovascular disease with approximately 360,000 symptomatic patients in the United States and EU5 SALT LAKE CITY ,

RHEA-AI

neutral

RXRX Data

Websitewww.recursionpharma.com
Security nameRecursion Pharmaceuticals Inc - Class A
Issue typecs
Sic code2836
Employees218

About Recursion Pharmaceuticals Inc

Recursion is a clinical-stage biotechnology company decoding biology by integrating technological innovations across biology, chemistry, automation, data science, and engineering, with the goal of radically improving the lives of patients and industrializing drug discovery. Central to its mission is the Recursion Operating System, or Recursion OS, that combines an advanced infrastructure layer to generate what Recursion believes is one of the world's largest and fastest-growing proprietary biological and chemical datasets and the Recursion Map, a suite of custom software, algorithms, and machine learning tools that the company uses to explore foundational biology unconstrained by human bias and navigate to new biological insights which may accelerate its programs. biotechnology company scaling more like a technology company.